Tired, Pale, and Bleeding Silently: The Adenoma-to-Carcinoma Sequence in a 61-Year-Old Man With Right-Sided Colon Cancer
Student Name
Master of Science in Nursing Program, Aspen University
N510: Advanced Pathophysiology
Instructor Name
Month Day, Year
Tired, Pale, and Bleeding Silently: The Adenoma-to-Carcinoma Sequence in a 61-Year-Old Man With Right-Sided Colon Cancer
Cancer is a disease of accumulated genetic damage in which cells escape the controls that normally govern their growth, survival, and location. Colorectal cancer is the classic model of how that damage accumulates step by step, because its precursor lesions can be seen and removed. This paper follows a composite patient whose colon cancer presented as iron deficiency anemia, explains the molecular pathways from normal mucosa to invasive cancer, links the mechanism to his presentation, and draws implications for screening and advanced nursing practice.
The Case
Mr. L. is a composite 61-year-old warehouse supervisor who reports three months of fatigue and shortness of breath on stairs. He has never had colorectal cancer screening. His hemoglobin is 9.2 g/dL with small red cells, a low ferritin, and no visible blood in his stool. A fecal immunochemical test is positive. Colonoscopy finds a 4 cm ulcerated mass in the ascending colon, biopsied as adenocarcinoma, and two small tubular adenomas in the sigmoid colon, which are removed. Staging imaging shows no distant spread.
The Adenoma-to-Carcinoma Sequence
Fearon and Vogelstein (1990) proposed a genetic model in which colorectal cancer develops through a series of mutations that accumulate over years as normal mucosa becomes an adenoma and then a carcinoma. The first step is usually loss of function of the APC gene, a tumor suppressor that normally keeps beta-catenin in check. Without APC, beta-catenin accumulates and drives the proliferation of colonic crypt cells, producing a small adenoma. Activating mutations in the KRAS oncogene then promote further growth, and loss of genes on chromosome 18q, including SMAD4, weakens growth-inhibitory signaling. Mutation of TP53, often a late event, removes a key checkpoint that halts division or triggers apoptosis when DNA is damaged, allowing the transition to invasive cancer.
The model's central insight is that no single mutation causes cancer; the number and combination of changes matter more than their exact order. An adenoma is a lesion partway along the road, which is why removing adenomas prevents cancer. The process typically takes a decade or more, creating a long window for screening.
Other Pathways and the Hallmarks of Cancer
Not all colorectal cancers follow the classic chromosomal instability pathway. About 15 percent arise through microsatellite instability, in which defects in DNA mismatch repair genes allow errors to accumulate throughout the genome; some are inherited, as in Lynch syndrome, and most are sporadic. Others arise from serrated polyps through a pathway involving BRAF mutation and widespread methylation that silences tumor suppressor genes (Dekker et al., 2019). The pathway matters clinically, because mismatch repair-deficient tumors respond differently to treatment and may signal an inherited syndrome in relatives.
Whatever the pathway, the resulting cells share the hallmark capacities of cancer described in the course text: sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, induction of blood vessel growth, and the ability to invade and metastasize (McCance & Huether, 2019). Mr. L.'s ulcerated mass shows several of these: it grew large, recruited a blood supply fragile enough to bleed, and invaded the colon wall.
Linking Mechanism to the Findings
Mr. L.'s presentation follows from the tumor's location and biology. Tumors of the right colon, where stool is still liquid, rarely cause obstruction early and tend to grow large before symptoms appear. Their surfaces, supplied by fragile new vessels, bleed slowly and continuously, and the blood is mixed into stool and not seen. Over months the steady loss depletes iron stores, producing microcytic anemia and the fatigue and dyspnea he describes. The positive fecal immunochemical test detected that hidden bleeding. The small adenomas in his sigmoid colon show the earlier stages of the same process at work elsewhere in his colon, a reminder that the conditions that produced one cancer produce polyps throughout the organ.
How the Mechanism Guides Treatment
Tumor biology now shapes treatment as well as understanding. Mr. L.'s localized tumor will be removed surgically with the surrounding lymph nodes, and the pathologic stage, determined by how deeply the tumor invaded the bowel wall and whether nodes contain cancer, will decide whether he is offered chemotherapy afterward. His tumor tissue will also be tested for mismatch repair deficiency and, if the disease ever spreads, for mutations such as KRAS and BRAF. These results matter because tumors with mismatch repair deficiency carry many mutations that make them visible to the immune system and often respond well to immune checkpoint inhibitors, while KRAS mutations predict that certain antibody therapies targeting the epidermal growth factor receptor will not work (Dekker et al., 2019).
For the nurse, this means explaining to patients why their tissue is being tested, why two people with colon cancer may receive very different treatments, and why the result of a tumor test may lead to a conversation about genetic testing for the family. Pathophysiology, in other words, has become part of everyday oncology nursing conversations.
Screening and Nursing Implications
Because the adenoma-to-carcinoma sequence is slow and its precursors are removable, screening prevents cancer as well as detecting it early. Current federal task force guidance calls for average-risk adults to begin screening at 45 and continue through 75, using stool-based tests such as annual fecal immunochemical testing or direct visualization such as colonoscopy every 10 years (US Preventive Services Task Force et al., 2021). Mr. L. was screening-eligible for more than a decade before his diagnosis.
For advanced practice nurses, the mechanism shapes several actions. Unexplained iron deficiency anemia in an adult man or a postmenopausal woman should prompt evaluation for gastrointestinal bleeding, not simply iron replacement. Tumor testing for mismatch repair deficiency, now standard for newly diagnosed colorectal cancer, may identify Lynch syndrome and trigger counseling and earlier screening for relatives. And every unscreened adult in a primary care panel represents a years-long window in which a removable adenoma could be found before it becomes a cancer.
Conclusion
Mr. L.'s cancer began, most likely, as a small adenoma driven by loss of APC and grew through additional mutations into an invasive tumor that bled slowly into his stool for months. The adenoma-to-carcinoma sequence explains his anemia, the location-specific way his cancer announced itself, and the other polyps in his colon. It also explains why screening works: a process that takes a decade to unfold gives clinicians many chances to interrupt it, and advanced practice nurses are well placed to make sure patients take one.
References
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019). Colorectal cancer. The Lancet, 394(10207), 1467-1480. https://doi.org/10.1016/S0140-6736(19)32319-0
Fearon, E. R., & Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell, 61(5), 759-767. https://doi.org/10.1016/0092-8674(90)90186-I
McCance, K. L., & Huether, S. E. (2019). Pathophysiology: The biologic basis for disease in adults and children (8th ed.). Elsevier.
US Preventive Services Task Force, Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Krist, A. H., Kubik, M., Li, L., Ogedegbe, G., Owens, D. K., Pbert, L., Silverstein, M., Stevermer, J., Tseng, C.-W., & Wong, J. B. (2021). Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA, 325(19), 1965-1977. https://doi.org/10.1001/jama.2021.6238
How this N 510 Module 4 example is structured
N510 Module 4 covers cancer, and in many sections the written work asks you to explain the pathophysiology of a cancer and connect it to a patient's presentation. Aspen does not publish module deliverables, so check your classroom for the exact prompt. This example explains the molecular sequence gene by gene with the original source, adds the alternative pathways and the hallmarks of cancer, maps each finding to the tumor's biology and location, and ends with screening and advanced practice implications.
N510 Module 4 questions, answered
What does N510 Module 4 usually ask for?
The module covers cancer, and the written work commonly asks you to explain the pathophysiology of a specific cancer, including genetic and cellular mechanisms, and relate it to a patient's presentation and care. Aspen does not publish module deliverables, so your classroom's instructions govern.
What is the adenoma-to-carcinoma sequence?
A model, proposed by Fearon and Vogelstein, in which colorectal cancer develops through accumulating mutations as normal mucosa becomes an adenoma and then a carcinoma, typically beginning with loss of APC and later involving KRAS, loss of 18q genes such as SMAD4 and TP53. It explains why removing adenomas prevents cancer.
Why do right-sided colon cancers cause anemia?
They tend to grow large before causing obstruction because stool is still liquid in the right colon, and their fragile surfaces bleed slowly into the stool, where the blood is not visible. Over months this depletes iron and causes iron deficiency anemia.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Aspen University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.